Literature DB >> 20413003

The Australian model of immunization advice and vaccine funding.

Terry M Nolan1.   

Abstract

The Australian Government has implemented new arrangements for public funding of vaccines over the past 5 years. By utilising the standard Pharmaceutical Benefits Advisory Committee (PBAC) application process, whether for funding under the National Immunisation Program Schedule (NIP) or under the Pharmaceutical Benefits Scheme (PBS), a predictable and transparent process for vaccine funding recommendations has been established. This process uses the high-level technical resources available through the Australian Technical Advisory Group on Immunisation (ATAGI) to ensure that both vaccine manufacturers and the PBAC are optimally informed about all relevant aspects of population benefits and delivery of vaccines. ATAGI has a long-standing and mutually beneficial dialogue with State and Territory Governments, providers, and vaccine manufacturers to ensure that pipeline awareness, supply issues, and all relevant scientific and clinical details are well understood.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413003     DOI: 10.1016/j.vaccine.2010.02.038

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Overcoming perceptions of financial barriers to rotavirus vaccine introduction in Asia.

Authors:  E Anthony S Nelson; Ciro A de Quadros; Mathuram Santosham; Umesh D Parashar; Duncan Steele
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

2.  Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study.

Authors:  Anita E Heywood; Han Wang; Kristine K Macartney; Peter McIntyre
Journal:  Bull World Health Organ       Date:  2014-06-13       Impact factor: 9.408

3.  Childhood Vaccination Mandates: Scope, Sanctions, Severity, Selectivity, and Salience.

Authors:  Katie Attwell; Mark C Navin
Journal:  Milbank Q       Date:  2019-09-16       Impact factor: 4.911

Review 4.  Economic evaluation of vaccines in Canada: A systematic review.

Authors:  Ayman Chit; Jason K H Lee; Minsup Shim; Van Hai Nguyen; Paul Grootendorst; Jianhong Wu; Robert Van Exan; Joanne M Langley
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

Review 5.  Modelling the epidemiology of infectious diseases for decision analysis: a primer.

Authors:  Mark Jit; Marc Brisson
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.981

6.  Current situation, causes, and countermeasures to NIP vaccine shortages in Guangzhou, China.

Authors:  Zhiqun Li; Jindong Xu; Jianxiong Xu; Huifeng Tan; Chunhuan Zhang
Journal:  Hum Vaccin Immunother       Date:  2019-08-12       Impact factor: 3.452

7.  Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine.

Authors:  Julianne Bayliss; Michael Nissen; Damita Prakash; Peter Richmond; Kyu-Bin Oh; Terry Nolan
Journal:  Hum Vaccin Immunother       Date:  2020-06-23       Impact factor: 3.452

Review 8.  Towards the eradication of HPV infection through universal specific vaccination.

Authors:  Piergiorgio Crosignani; Antonella De Stefani; Gaetano Maria Fara; Andrea M Isidori; Andrea Lenzi; Carlo Antonio Liverani; Alberto Lombardi; Francesco Saverio Mennini; Giorgio Palu'; Sergio Pecorelli; Andrea P Peracino; Carlo Signorelli; Gian Vincenzo Zuccotti
Journal:  BMC Public Health       Date:  2013-07-11       Impact factor: 3.295

9.  Value Frameworks for Vaccines: Which Dimensions Are Most Relevant?

Authors:  Jeroen Luyten; Roselinde Kessels; Corinne Vandermeulen; Philippe Beutels
Journal:  Vaccines (Basel)       Date:  2020-10-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.